Taiwan’s Gongwin Biopharm Holdings announced Wednesday that its subsidiary Gongwin Taiwan Medical Technology secured two licensing agreements for PTS302, a lung cancer treatment targeting central airway obstruction.
The first deal with Malaysia-based Company F grants product registration, commercialization, and distribution rights for PTS-302 in Malaysia, while Gongwin Taiwan will receive signing fees and milestone payments. The partnership builds on a memorandum of understanding signed in May with the Malaysian firm, which has over 30 years of experience in oncology and respiratory medicine.
Simultaneously, Gongwin Taiwan signed a separate memorandum with Taiwan-based Company G to conduct bridging clinical trials and seek regulatory approval for PTS-302 in Taiwan. The companies plan to jointly apply for National Health Insurance reimbursement and co-market the product locally, sharing development costs and future sales profits.
PTS302 received approval in China and targets malignant airway obstruction in central lung cancer, a condition with high mortality rates. The drug has already been approved by China’s Drug Administration and is expected to be officially licensed soon.
According to company executives, the drug addresses a significant unmet medical need in treating advanced lung cancer cases where tumors block airways, causing breathing difficulties and threatening patient survival. The partnerships are expected to boost financial performance and strengthen presence across Asia-Pacific pharmaceutical markets.
The treatment utilizes minimally invasive targeted tumor ablation technology, directly injecting medication into tumor sites to minimize impact on surrounding healthy tissue.
